NATCO Pharma Limited (BOM:524816)

Market Cap	147.56B -29.9%
Revenue (ttm)	45.63B +6.6%
Net Income	15.57B -16.5%
EPS	86.94 -16.5%
Shares Out	n/a
PE Ratio	9.48
Forward PE	17.42
Dividend	3.50 (0.41%)
Ex-Dividend Date	Nov 20, 2025

Volume	82,829
Average Volume	40,889
Open	825.20
Previous Close	839.90
Day's Range	815.05 - 834.00
52-Week Range	660.05 - 1,242.45
Beta	n/a
RSI	42.68
Earnings Date	Feb 12, 2026

About NATCO Pharma

NATCO Pharma Limited, a pharmaceutical company, engages in the research and development, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates in India, the United States, and internationally. The company offers formulations in various therapeutic areas, including cancers of blood, liver, kidney, lung, brain, breast, and ovary; and APIs in various categories, such as oncology, central nervous system, pain management, and cardiovascular care. It also provides orthopedic products...

• Industry: Pharmaceutical Preparations
• Founded: 1981
• Employees: 4,199
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 524816

Financial Performance

In fiscal year 2025, NATCO Pharma's revenue was 44.32 billion, an increase of 10.74% compared to the previous year's 40.02 billion. Earnings were 18.85 billion, an increase of 35.81%.